Epigral Registers Strong Q3 FY24-25 Growth, Looks Towards Future Expansion

Epigral, a major integrated chemical manufacturer, reported strong financial performance in Q3 FY24-25. PAT for the company improved by 110% to Rs. 104 crore, and revenue improved by 37% to Rs. 649 crore over Q3 FY24. Epigral's diversification strategy has been instrumental in its steady growth, with the Derivatives business accounting for 54% of revenue in 9MFY25. The firm is augmenting its CPVC Resin and Epichlorohydrin capacity, anticipating volume contribution from the projects from FY2027 onwards. Epigral seeks to enhance its integrated complex and serve diversified industries for stakeholder value creation.

 

Source: Indian Chemical News